CLL patients from an ongoing clinical trial who were treated with humanized anti-CD74 (milatuzumab) showed a decrease in SLAMF5/CD84 mRNA and protein levels in milatuzumab-treated cells. This evidence concerns the gene CD84 and B-cell chronic lymphocytic leukemia.